Scale-independent microfluidic production of cationic liposomal adjuvants and development of enhanced lymphatic targeting strategies

Research output: Contribution to journalArticle

Abstract

Cationic liposomes prepared from dimethyldioctadecylammonium bromide (DDAB) and trehalose 6,6′-dibehenate (TDB) are strong liposomal adjuvants. As with many liposome formulations, within the laboratory DDAB:TDB is commonly prepared by the thin-film method, which is difficult to scale-up and gives high batch-To-batch variability. In contrast, controllable technologies such as microfluidics offer robust, continuous, and scale-independent production. Therefore, within this study, we have developed a microfluidic production method for cationic liposomal adjuvants that is scale-independent and produces liposomal adjuvants with analogous biodistribution and immunogenicity compared to those produced by the small-scale lipid hydration method. Subsequently, we further developed the DDAB:TDB adjuvant system to include a lymphatic targeting strategy using microfluidics. By exploiting a biotin-Avidin complexation strategy, we were able to manipulate the pharmacokinetic profile and enhance targeting and retention of DDAB:TDB and antigen within the lymph nodes. Interestingly, redirecting these cationic liposomal adjuvants did not translate into notably improved vaccine efficacy.

LanguageEnglish
Pages4372-4386
Number of pages15
JournalMolecular Pharmaceutics
Volume16
Issue number10
Early online date22 Aug 2019
DOIs
Publication statusPublished - 7 Oct 2019

Fingerprint

Microfluidics
Liposomes
Avidin
Biotin
Vaccines
Pharmacokinetics
Lymph Nodes
Technology
Lipids
Antigens
dimethyldioctadecylammonium
trehalose 6,6'-dibehenate

Keywords

  • microfluidics
  • manufacture
  • vaccine adjuvants
  • cationic liposomes
  • lymphatic targeting

Cite this

@article{2fd0eca452d34e2aa0d4cc9c864535bb,
title = "Scale-independent microfluidic production of cationic liposomal adjuvants and development of enhanced lymphatic targeting strategies",
abstract = "Cationic liposomes prepared from dimethyldioctadecylammonium bromide (DDAB) and trehalose 6,6′-dibehenate (TDB) are strong liposomal adjuvants. As with many liposome formulations, within the laboratory DDAB:TDB is commonly prepared by the thin-film method, which is difficult to scale-up and gives high batch-To-batch variability. In contrast, controllable technologies such as microfluidics offer robust, continuous, and scale-independent production. Therefore, within this study, we have developed a microfluidic production method for cationic liposomal adjuvants that is scale-independent and produces liposomal adjuvants with analogous biodistribution and immunogenicity compared to those produced by the small-scale lipid hydration method. Subsequently, we further developed the DDAB:TDB adjuvant system to include a lymphatic targeting strategy using microfluidics. By exploiting a biotin-Avidin complexation strategy, we were able to manipulate the pharmacokinetic profile and enhance targeting and retention of DDAB:TDB and antigen within the lymph nodes. Interestingly, redirecting these cationic liposomal adjuvants did not translate into notably improved vaccine efficacy.",
keywords = "microfluidics, manufacture, vaccine adjuvants, cationic liposomes, lymphatic targeting",
author = "Roces, {Carla B.} and Swapnil Khadke and Dennis Christensen and Yvonne Perrie",
year = "2019",
month = "10",
day = "7",
doi = "10.1021/acs.molpharmaceut.9b00730",
language = "English",
volume = "16",
pages = "4372--4386",
journal = "Molecular Pharmaceutics",
issn = "1543-8384",
publisher = "American Chemical Society",
number = "10",

}

TY - JOUR

T1 - Scale-independent microfluidic production of cationic liposomal adjuvants and development of enhanced lymphatic targeting strategies

AU - Roces, Carla B.

AU - Khadke, Swapnil

AU - Christensen, Dennis

AU - Perrie, Yvonne

PY - 2019/10/7

Y1 - 2019/10/7

N2 - Cationic liposomes prepared from dimethyldioctadecylammonium bromide (DDAB) and trehalose 6,6′-dibehenate (TDB) are strong liposomal adjuvants. As with many liposome formulations, within the laboratory DDAB:TDB is commonly prepared by the thin-film method, which is difficult to scale-up and gives high batch-To-batch variability. In contrast, controllable technologies such as microfluidics offer robust, continuous, and scale-independent production. Therefore, within this study, we have developed a microfluidic production method for cationic liposomal adjuvants that is scale-independent and produces liposomal adjuvants with analogous biodistribution and immunogenicity compared to those produced by the small-scale lipid hydration method. Subsequently, we further developed the DDAB:TDB adjuvant system to include a lymphatic targeting strategy using microfluidics. By exploiting a biotin-Avidin complexation strategy, we were able to manipulate the pharmacokinetic profile and enhance targeting and retention of DDAB:TDB and antigen within the lymph nodes. Interestingly, redirecting these cationic liposomal adjuvants did not translate into notably improved vaccine efficacy.

AB - Cationic liposomes prepared from dimethyldioctadecylammonium bromide (DDAB) and trehalose 6,6′-dibehenate (TDB) are strong liposomal adjuvants. As with many liposome formulations, within the laboratory DDAB:TDB is commonly prepared by the thin-film method, which is difficult to scale-up and gives high batch-To-batch variability. In contrast, controllable technologies such as microfluidics offer robust, continuous, and scale-independent production. Therefore, within this study, we have developed a microfluidic production method for cationic liposomal adjuvants that is scale-independent and produces liposomal adjuvants with analogous biodistribution and immunogenicity compared to those produced by the small-scale lipid hydration method. Subsequently, we further developed the DDAB:TDB adjuvant system to include a lymphatic targeting strategy using microfluidics. By exploiting a biotin-Avidin complexation strategy, we were able to manipulate the pharmacokinetic profile and enhance targeting and retention of DDAB:TDB and antigen within the lymph nodes. Interestingly, redirecting these cationic liposomal adjuvants did not translate into notably improved vaccine efficacy.

KW - microfluidics

KW - manufacture

KW - vaccine adjuvants

KW - cationic liposomes

KW - lymphatic targeting

U2 - 10.1021/acs.molpharmaceut.9b00730

DO - 10.1021/acs.molpharmaceut.9b00730

M3 - Article

VL - 16

SP - 4372

EP - 4386

JO - Molecular Pharmaceutics

T2 - Molecular Pharmaceutics

JF - Molecular Pharmaceutics

SN - 1543-8384

IS - 10

ER -